Enhancement of ␥-aminobutyric acid type A receptor (GABA A R)-mediated inhibition is a property of most general anesthetics and a candidate for a molecular mechanism of anesthesia. Intravenous anesthetics, including etomidate, propofol, barbiturates, and neuroactive steroids, as well as volatile anesthetics and long-chain alcohols, all enhance GABA A R function at anesthetic concentrations. The implied existence of a receptor site for anesthetics on the GABA A R protein was supported by identification, using photoaffinity labeling, of a binding site for etomidate within the GABA A R transmembrane domain at the -␣ subunit interface; the etomidate analog Inhibition by barbiturates, which was pharmacologically specific and stereospecific, and by propofol was only partial, consistent with allosteric interactions, whereas isoflurane inhibition was nearly complete, apparently competitive. Protein sequencing showed that propofol inhibited to the same extent the photolabeling of ␣1Met-236 and Met-286. These results indicate that several classes of general anesthetics modulate etomidate binding to the GABA A R: isoflurane binds directly to the site with millimolar affinity, whereas propofol and barbiturates inhibit binding but do not bind in a mutually exclusive manner with etomidate. ␥-Aminobutyric acid type A receptors (GABA A Rs) 3 are major mediators of brain inhibitory neurotransmission and participate in most circuits and behavioral pathways relevant to normal and pathological function. Their regulation may underlie many psychiatric/neurological disorders. GABA A Rs are subject to modulation by endogenous neurosteroids, as well as myriad clinically important central nervous system drugs, including general anesthetics, benzodiazepines, and ethanol (1-3). The mechanism of GABA A R modulation by these different classes of drugs is of major interest, including the localization of their binding sites in the receptor.Each GABA A R is made up of five homologous subunits that associate around a central axis that forms the ion channel. Each subunit consists of a large extracellular N-terminal domain, a transmembrane domain made up of a loose bundle of four transmembrane ␣-helices, and a cytoplasmic domain made up of the amino acids located in the primary structure between the M3 and M4 helices. In an ␣ 2  2 ␥ GABA A R, the neurotransmitter-binding sites are located in the extracellular domain at the interfaces between the  and ␣ subunits, two sites per receptor, whereas the benzodiazepine sites are at an equivalent position at the ␣-␥ subunit interface, one per receptor (4).Most general anesthetics enhance GABA A R responses in vitro at concentrations that produce immobilization in vivo, suggesting a link between the GABA A R and anesthesia (5, 6). The expression of receptors containing chimeric subunits combining sequences from subunits conferring different anesthetic sensitivities led to the identification of two residues that determine the sensitivity of the GABA A R to volatile agents and alcohols (7). These residue...